The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Shorespan-007: Phase 3 study of bomedemstat versus hydroxyurea in essential thrombocythemia naive to cytoreductive therapy.
 
Kristen Pettit
Consulting or Advisory Role - AbbVie; Merck
Travel, Accommodations, Expenses - Merck
 
Yuka Sugimoto
Honoraria - Novartis; Pharmaessentia Japan K.K
Research Funding - Incyte Japan; MSD K.K; Toyo Kohan Co., Ltd.
 
Eran Zimran
No Relationships to Disclose
 
Yoshimitsu Shimomura
No Relationships to Disclose
 
Hiroki Yamaguchi
Honoraria - Abbvie; Astellas Pharma; AstraZeneca Japan; Daiichi Sankyo; Nippon Shinyaku; Novartis
Research Funding - Abbvie (Inst); Novartis (Inst)
 
Hans Hasselbach
Consulting or Advisory Role - AOP Orphan Pharmaceuticals; Incyte
Research Funding - Novartis
 
Jean-Jacques Kiladjian
Consulting or Advisory Role - Abbvie; AOP Orphan Pharmaceuticals; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Novartis; PharmaEssentia
Travel, Accommodations, Expenses - Novartis
 
Steffen Koschmieder
Employment - RWTH Aachen University
Honoraria - ABBVIE; AOP Orphan Pharmaceuticals; ARIAD; Bristol-Myers Squibb; Celgene; Geron; Incyte; iOMEDICO; Janssen; Kartos Therapeutics; MSD; Novartis; Pfizer; Roche; Shire
Consulting or Advisory Role - Abbvie; AOP Orphan Pharmaceuticals; Baxalta; Bristol-Myers Squibb; Celgene; CTI; Geron; GlaxoSmithKline; Incyte; Janssen; MPN Advocates Network; MSD; Novartis; Pfizer; PharmaEssentia; Protagonist Therapeutics; Roche; Sanofi; Sierra Oncology
Research Funding - AOP Orphan Pharmaceuticals; Bristol-Myers Squibb; Janssen; Novartis
Patents, Royalties, Other Intellectual Property - RWTH Aachen University
Travel, Accommodations, Expenses - Abbvie; Alexion Pharmaceuticals; AOP Orphan Pharmaceuticals; Baxalta; Bristol-Myers Squibb; Celgene; CTI; Geron; GlaxoSmithKline; Imago Biosciences; Incyte; iOMEDICO; Janssen; Kartos Therapeutics; MSD; Novartis; Pfizer; Protagonist Therapeutics; Sanofi; Shire; Sierra Oncology
Other Relationship - Associate Editor of Hemasphere; Co-Speaker of German Study Group for MPN (GSG-MPN) and GSG- MPN bioregistry; Member of EHA Guidelines Committee, Chairman Hemostasis Working Party of DGHO
 
Harinder Gill
Honoraria - Astellas Pharma; BMS; GlaxoSmithKline; MSD; Novartis; Otsuka; Pharmaessentia
Consulting or Advisory Role - GlaxoSmithKline; PharmaEssentia
Research Funding - Bristol-Myers Squibb/Celgene; MSD; Novartis; Pharmaessentia
Patents, Royalties, Other Intellectual Property - COMPOSITIONS AND METHODS FOR FAST MULTIPLEXED SCREENING AND MONITORING OF NPM1 MUTATIONS (International publication number: WO 2023/011624 Al); The University of Hong Kong currently holds two United States (US) patents (7,521,071 B2 and 8,906,422 B2), one Japanese patent (4786341) and one European patent (EP 1562616 B1) for the use of oral arsenic trioxide in the treatment of leukemias and lympho (Inst)
Travel, Accommodations, Expenses - BMS; Jacobson Pharma Corporation (Hong Kong); MSD; Novartis; Otsuka; Pfizer; Pharmaessentia
 
Natalia Curto-Garcia
Consulting or Advisory Role - Medscape
 
Alejandro Berkovits
Consulting or Advisory Role - Bristol Myers Squibb Foundation
Speakers' Bureau - Janssen
Expert Testimony - Novartis
Travel, Accommodations, Expenses - Janssen
 
Ahmet Muzaffer Demir
No Relationships to Disclose
 
Tsai-Yun Chen
No Relationships to Disclose
 
Stefan Scheding
Consulting or Advisory Role - Active Biotech (Inst); GlaxoSmithKline (Inst)
 
Claudia Carmona
No Relationships to Disclose
 
Alessandro Vannucchi
Honoraria - Abbvie; AOP Health; GlaxoSmithKline; Incyte; Italfarmaco; Menarini; Novartis
Consulting or Advisory Role - Italfarmaco
Research Funding - iOnctura
 
Keita Kirito
Honoraria - Abbvie; GlaxoSmithKline; Novartis; Pharmaessentia
 
Shiyu Zhang
Employment - MSD
Stock and Other Ownership Interests - MSD
Travel, Accommodations, Expenses - MSD
 
Uzor Ogbu
Employment - Merck
Stock and Other Ownership Interests - Merck; Roche
 
David Ross
Consulting or Advisory Role - Avance Clinical (Inst); GlaxoSmithKline (Inst); Keros Therapeutics (Inst); Menarini (Inst); Merck; Novartis (Inst)
Speakers' Bureau - Novartis
Research Funding - GlaxoSmithKline (Inst); Imago Pharma (Inst); Incyte (Inst); Jubilant Therapeutics (Inst); Kartos Therapeutics (Inst); Keros Therapeutics (Inst); Merck (Inst); MorphoSys (Inst); Novartis (Inst); Protagonist Therapeutics (Inst); Sumitomo Pharma Oncology (Inst)
(OPTIONAL) Uncompensated Relationships - Australasian Leukaemia and Lymphoma Group